The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid‐induced osteoporosis

2021 ◽  
Author(s):  
Nat Nasomyont ◽  
Cuixia Tian ◽  
Lindsey Hornung ◽  
Jane Khoury ◽  
Paul M. Hochwalt ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bisphosphonate Therapy ◽  
Vertebral Morphometry ◽  
Oral Bisphosphonate

Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy

2016 ◽  
Vol 54 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Ramesh Srinivasan ◽  
David Rawlings ◽  
Claire L. Wood ◽  
Tim Cheetham ◽  
Aura Cecilia Jimenez Moreno ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bisphosphonate Therapy ◽  
Oral Bisphosphonate

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy

2020 ◽  
Vol 30 (7) ◽  
pp. 599-610
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Irina Rybalsky ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Glucocorticoid Therapy ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate

scholarly journals Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy

2020 ◽  
Vol 13 ◽  
pp. 117955142097240
Author(s):  
Rebecca Ronsley ◽  
Nazrul Islam ◽  
Mehima Kang ◽  
Helen Nadel ◽  
Christopher Reilly ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bone Mineral ◽  
Comparative Effectiveness ◽  
Fragility Fractures ◽  
Estimating Equation ◽  
Treated Group ◽  
Bisphosphonate Therapy ◽  
Mineral Density

The objective of this study was to estimate the comparative effectiveness of bisphosphonate therapy on bone mineral density (BMD) in patients with corticosteroid-treated Duchenne muscular dystrophy (DMD). A retrospective, comparative effectiveness study evaluating changes in BMD and fragility fractures in patients with DMD presenting to British Columbia Children’s Hospital from 1989 to 2017 was conducted. Marginal structural generalized estimating equation models weighted by stabilized inverse-probability of treatment weights were used to estimate the comparative effectiveness of therapy on BMD. Of those treated with bisphosphonates (N = 38), 7 (18.4%), 17 (44.7%), and 14 (36.8%) cases were treated with pamidronate, zoledronic acid, or a combination of both, respectively, while 36 cases of DMD were untreated. Mean age of bisphosphonate initiation was 9.2 (SD 2.7) years. Mean fragility fractures declined from 3.5 to 1.0 following bisphosphonate therapy. Compared to the treated group, the untreated group had an additional 0.63-SD decrease (95% confidence interval [CI]: −1.18, −0.08, P = .026) in total BMD and an additional 1.04-SD decrease (95% CI: −1.74, −0.34; P = .004) in the left hip BMD, but the change in lumbar spine BMD (0.15, 95% CI: −0.36, 0.66; P = .57) was not significant. Bisphosphonate therapy may slow the decline in BMD in boys with corticosteroid-treated DMD compared to untreated counterparts. Total number of fragility fractures decreased following bisphosphonate therapy.

Fracture incidence and bisphosphonate therapy in boys with Duchenne Muscular Dystrophy

2015 ◽  
Author(s):  
Nicola Crabtree ◽  
Wolfgang Hogler ◽  
Jaskiran Sahota ◽  
Dee Chapman ◽  
Jacky Walford ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bisphosphonate Therapy ◽  
Fracture Incidence
Sign in / Sign up

Export Citation Format

Share Document